
Koen De Smet, MD

## CERAMIC ON CERAMIC

## RECERF

Surgery in Ghent Belgium (ANCA CLINIC AZ Jan Palfijn Hospital Ghent)



## **Ceramic on Ceramic**

## RECERF

- Manufactured by MatOrtho Limited United Kingdom
- Minimal bone removal compared to total hip
- Ball-and-socket bearing with same size as the natural hip joint
- Less dislocation as with total hip, retaining the healthy femoral head
- No exposure to metal debris and metal ions, minimal risk for allergy
- Less risk for problems in female patients and small sizes
- Same importance for highly technical experience of hip joint surgeon as with MOM resurfacing

The ReCerf® Hip Resurfacing device has been extensively laboratory tested where the device was subjected to loads far in excess of those expected in a patient's own body such as falls (stumbling) and traumatic events such as head-on car crash to evaluate its performance limitations. Mechanical testing and state-of-art finite element analysis (computer modeling) investigated all aspects of performance of the device such as static and fatigue limits, joint simulator wear testing including micro-separation, head and cup fixation and predictive bone remodeling.

All testing meets or exceeds the design parameters.

Additionally, the fixation coating type is one that has been used for many years on metal total hip implants and exceeds all test standards. The ceramic material used in the components of the device has been use in total hips over 16 years and is supplied by the world leader in ceramic material.

As discussed above because ReCerf® is a new device, it does not yet have enough clinical data to predict all outcomes and no-one can know what unexpected issues may arise until a dataset of clinical evidence has been accumulated, however this extensive testing supports the use of the device in patients.

The first ReCerf® device was implanted on 24th September 2018 and more than 190 have been implanted since then. All patients continue to do well and their consultant's report no issues with the device. Patients are being followed up closely to ensure the continued success of the device and early reporting of any unexpected issues.